Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR

Publish date:: June 18, 2020

Key clinical point: Treatment of patients with type 2 diabetes with dapagliflozin cut the incidence of fast decline in estimated glomerular filtration rate.

Major finding: The 6-month to 4-year incidence of fast decline in eGFR was 27% on dapagliflozin and 37% on placebo.

Study details: A post-hoc analysis of 15,012 patients enrolled in DECLARE-TIMI 58.

Disclosures: DECLARE-TIMI 58 was sponsored by AstraZeneca, the company that markets dapagliflozin (Farxiga). Dr. Raz has been an advisor to and speaker on behalf of AstraZeneca as well as several other companies.

Citation:

Raz I et al. ADA 2020, Abstract 303-OR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,